Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Mean Number of Hypoglycemic Events Per Participant.
研究概览
简要总结
Diabetes control is often assessed by tests of glucose levels over time, such as the glycosylated hemoglobin A1c (HbA1c) and fructosamine. In the later stages of chronic kidney disease (CKD) there is limited data available on the utility of these tests. There are reasons to believe that the tests may be less accurate in this population. Continuous glucose monitoring (CGM) offers an effective method for understanding the totality of glucose exposure and incidence of both hyperglycemic and hypoglycemic excursions.
详细描述
In the proposed study Investigator plan to utilize CGM in patients with late stage CKD stages 3b-5 to 1) determine accuracy of HbA1c and serum fructosamine testing as measures of glucose control in patients with Type 2 Diabetes Mellitus (T2DM), 2) Better understand test characteristics in the late stage CKD population (correlation, linear equation, slope, Y intercept, average glucose at different HbA1c levels), 3) Develop a preliminary understanding of how test characteristics differ in late stage CKD compared to other patients with diabetes, 4) quantify time burden and number of episodes of hypoglycemia, 4) study hyperglycemic burden and 5) analyze glucose variability. The research staff will explain the study to patients that meet all inclusion criteria. Patients will get time to understand the study, review the consent document, ask questions to the PI, and then provide their consent to participate in the study. On Day 1 of the study, a CGM (Freestyle Libre) device will be placed on patients with CKD 3b-5 which will be worn for 14 consecutive days. Patients will return on Day 14 to remove the CGM device. HbA1c and fructosamine values will be drawn on Day 14 and these results will be compared with average glucose monitoring values as recorded on the CGM device. Incidence, duration, and severity of both hypoglycemic and hyperglycemic events will be analyzed. Investigators hypothesis that there will be significant variability in the serum HbA1c values when compared with calculated HbA1c from CGM readings. Investigators also hypothesize that the results will reflect a greater incidence of hypoglycemia in this population by CGM analysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years and older with ability to speak and understand English
- •Established diagnosis of type 2 Diabetes Mellitus
- •Chronic Kidney Disease (stages 3b, 4 or 5, eGFR (Glomerular Filtration Rate) < 45 ml/min, and not on dialysis) documented within 3 months of enrollment
排除标准
- •Type 2 Diabetes Mellitus.
- •Patient with End stage kidney disease on Dialysis.
- •Presence of Hemoglobinopathies.
- •Red blood cell transfusion in the last 12 weeks.
- •Hb < 9 g/dL documented within 3 months of enrollment - Dosing with an erythropoiesis stimulating agent is acceptable but dose must be stable for two months.
- •Use of acetaminophen on a daily basis.
- •Systemic steroid treatment in the past 12 weeks.
- •Greater than 50% dose change in diabetes medications or new diabetes medications started in the previous 8 weeks.
- •Currently pregnant.
结局指标
主要结局
Mean Number of Hypoglycemic Events Per Participant.
时间窗: 14 Days
Total number of hypoglycemic events per subject will be calculated during the study period. Mean number of events per subject will be analyzed.
Duration Hypoglycemic Events
时间窗: 14 Days
As monitoring device measures blood glucose level numerous time, duration of hypoglycemic event will be calculated in percent time per subject based on total duration of time subject wore CGM device.
Mean HbA1c
时间窗: 14 Days
HbA1c collected at end of the participation.
Mean Glucose Concentration Measured by CGM
时间窗: 14 Days
Mean glucose concentration (mg/dL) will be measured using measurements taken by CGM device.
Number of Participants With Hypoglycemic Events
时间窗: 14 Days
Hypoglycemic event will be considered when blood sugar level is \<=70 mg/dl. Detail information like time of event, number of subjects with an event, duration of event will be analyzed.
次要结局
- Mean Serum Fructosamine Concentration(14 Days)
- Determination of Serum Fructosamine(14 days)
研究者
Lubaina Presswala
Principal Investigator
Northwell Health